HomeAI · summaries
Storia in 2 fonti
Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27
Dr Reddy's Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US business pressures. However, operations in India, Europe, and emerging markets show healthy growth. New launches like Semaglutide and Abatacept are expected to drive future expansion. Margins are set to improve with better product mix and cost controls.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27
Dr Reddy's Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US business pressures. However, operations in India,…
- ·
Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in Canada
Dr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. This marks a significant step for the company in providing treatment for type 2 diabetes. Canada…
- ·
benzinga.com
Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push - Dr Reddy's Laboratories (NYSE:RD
Dr. Reddy's launched generic Semaglutide Injection in Canada, expanding its GLP-1 portfolio and strengthening its affordable diabetes treatment presence.